Proline oxidase
Proline dehydrogenase, mitochondrial is an enzyme that in humans is encoded by the PRODH gene.[1][2][3]
The protein encoded by this gene is a mitochondrial proline dehydrogenase which catalyzes the first step in proline catabolism. Deletion of this gene has been associated with type I hyperprolinemia. The gene is located on chromosome 22q11.21, a region which has also been associated with the contiguous gene deletion syndromes: DiGeorge syndrome and CATCH22 syndrome.[3]
Function
Proline oxidase, or proline dehydrogenase, functions as the initiator of the proline cycle. Proline metabolism is especially important in nutrient stress because proline is readily available from the breakdown of extracellular matrix (ECM), and the degradation of proline through the proline cycle initiated by proline oxidase (PRODH), a mitochondrial inner membrane enzyme, can generate ATP. This degradative pathway generates glutamate and alpha-ketoglutarate, products that can play an anaplerotic role for the TCA cycle.The proline cycle is also in a metabolic interlock with the pentose phosphate pathway providing another bioenergetic mechanism. The induction of stress either by glucose withdrawal or by treatment with rapamycin, stimulated degradation of proline and increased PRODH catalytic activity. Under these conditions PRODH was responsible, at least in part, for maintenance of ATP levels. Activation of AMP-activated protein kinase (AMPK), the cellular energy sensor, by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), also markedly upregulated PRODH and increased PRODH-dependent ATP levels, further supporting its role during stress. Glucose deprivation increased intracellular proline levels, and expression of PRODH activated the pentose phosphate pathway. Therefore, the induction of the proline cycle under conditions of nutrient stress may be a mechanism by which cells switch to a catabolic mode for maintaining cellular energy levels.[4]
Clinical significance
Mutations in the PRODH gene are associated with Proline Dehydrogenase deficiency. Many case studies have reported on this genetic disorder. In one such case study, 4 unrelated patients with HPI and a severe neurologic phenotype were shown to have the following common features: psychomotor delay from birth, often associated with hypotonia, severe language delay, autistic features, behavioral problems, and seizures. One patient who was heterozygous for a 22q11 microdeletion also had dysmorphic features. Four previously reported patients with HPI and neurologic involvement had a similar phenotype. This case study showed that Hyperprolinemia, Type I (HPI) may not always be a benign condition, and that the severity of the clinical phenotype appears to correlate with the serum proline level.[5] Still, in another case study, clinical features from 4 unrelated patients included early motor and cognitive developmental delay, speech delay, autistic features, hyperactivity, stereotypic behaviors, and seizures. All patients had increased plasma and urine proline levels. All patients had biallelic mutations in the PRODH gene, often with several variants on the same allele. Residual enzyme activity ranged from null in the most severely affected patient to 25 to 30% in those with a relatively milder phenotype.[6]
References
- ↑ Campbell HD, Webb GC, Young IG (Nov 1997). "A human homologue of the Drosophila melanogaster sluggish-A (proline oxidase) gene maps to 22q11.2, and is a candidate gene for type-I hyperprolinaemia". Human Genetics 101 (1): 69–74. doi:10.1007/s004390050589. PMID 9385373.
- ↑ Gogos JA, Santha M, Takacs Z, Beck KD, Luine V, Lucas LR, Nadler JV, Karayiorgou M (Apr 1999). "The gene encoding proline dehydrogenase modulates sensorimotor gating in mice". Nature Genetics 21 (4): 434–9. doi:10.1038/7777. PMID 10192398.
- 1 2 "Entrez Gene: PRODH proline dehydrogenase (oxidase) 1".
- ↑ Pandhare J, Donald SP, Cooper SK, Phang JM (Jul 2009). "Regulation and function of proline oxidase under nutrient stress". Journal of Cellular Biochemistry 107 (4): 759–68. doi:10.1002/jcb.22174. PMID 19415679.
- ↑ Afenjar A, Moutard ML, Doummar D, Guët A, Rabier D, Vermersch AI, Mignot C, Burglen L, Heron D, Thioulouse E, de Villemeur TB, Campion D, Rodriguez D (Oct 2007). "Early neurological phenotype in 4 children with biallelic PRODH mutations". Brain & Development 29 (9): 547–52. doi:10.1016/j.braindev.2007.01.008. PMID 17412540.
- ↑ Perry TL, Hardwick DF, Lowry RB, Hansen S (May 1968). "Hyperprolinaemia in two successive generations of a North American Indian family". Annals of Human Genetics 31 (4): 401–7. doi:10.1111/j.1469-1809.1968.tb00573.x. PMID 4299764.
Further reading
- Kempf L, Nicodemus KK, Kolachana B, Vakkalanka R, Verchinski BA, Egan MF, Straub RE, Mattay VA, Callicott JH, Weinberger DR, Meyer-Lindenberg A (Nov 2008). Katsanis N, ed. "Functional polymorphisms in PRODH are associated with risk and protection for schizophrenia and fronto-striatal structure and function". PLoS Genetics 4 (11): e1000252. doi:10.1371/journal.pgen.1000252. PMC 2573019. PMID 18989458.
- Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B (Sep 1997). "A model for p53-induced apoptosis". Nature 389 (6648): 300–5. doi:10.1038/38525. PMID 9305847.
- Donald SP, Sun XY, Hu CA, Yu J, Mei JM, Valle D, Phang JM (Mar 2001). "Proline oxidase, encoded by p53-induced gene-6, catalyzes the generation of proline-dependent reactive oxygen species". Cancer Research 61 (5): 1810–5. PMID 11280728.
- Liu H, Heath SC, Sobin C, Roos JL, Galke BL, Blundell ML, Lenane M, Robertson B, Wijsman EM, Rapoport JL, Gogos JA, Karayiorgou M (Mar 2002). "Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia". Proceedings of the National Academy of Sciences of the United States of America 99 (6): 3717–22. doi:10.1073/pnas.042700699. PMC 122590. PMID 11891283.
- Jacquet H, Raux G, Thibaut F, Hecketsweiler B, Houy E, Demilly C, Haouzir S, Allio G, Fouldrin G, Drouin V, Bou J, Petit M, Campion D, Frébourg T (Sep 2002). "PRODH mutations and hyperprolinemia in a subset of schizophrenic patients". Human Molecular Genetics 11 (19): 2243–9. doi:10.1093/hmg/11.19.2243. PMID 12217952.
- Maxwell SA, Rivera A (Mar 2003). "Proline oxidase induces apoptosis in tumor cells, and its expression is frequently absent or reduced in renal carcinomas". The Journal of Biological Chemistry 278 (11): 9784–9. doi:10.1074/jbc.M210012200. PMID 12514185.
- Jacquet H, Berthelot J, Bonnemains C, Simard G, Saugier-Veber P, Raux G, Campion D, Bonneau D, Frebourg T (Jan 2003). "The severe form of type I hyperprolinaemia results from homozygous inactivation of the PRODH gene". Journal of Medical Genetics 40 (1): e7. doi:10.1136/jmg.40.1.e7. PMC 1735267. PMID 12525555.
- Williams HJ, Williams N, Spurlock G, Norton N, Zammit S, Kirov G, Owen MJ, O'Donovan MC (Jul 2003). "Detailed analysis of PRODH and PsPRODH reveals no association with schizophrenia". American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 120B (1): 42–6. doi:10.1002/ajmg.b.20049. PMID 12815738.
- Li T, Ma X, Sham PC, Sun X, Hu X, Wang Q, Meng H, Deng W, Liu X, Murray RM, Collier DA (Aug 2004). "Evidence for association between novel polymorphisms in the PRODH gene and schizophrenia in a Chinese population". American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 129B (1): 13–5. doi:10.1002/ajmg.b.30049. PMID 15274030.
- Zhang M, White TA, Schuermann JP, Baban BA, Becker DF, Tanner JJ (Oct 2004). "Structures of the Escherichia coli PutA proline dehydrogenase domain in complex with competitive inhibitors". Biochemistry 43 (39): 12539–48. doi:10.1021/bi048737e. PMID 15449943.
- Jacquet H, Demily C, Houy E, Hecketsweiler B, Bou J, Raux G, Lerond J, Allio G, Haouzir S, Tillaux A, Bellegou C, Fouldrin G, Delamillieure P, Ménard JF, Dollfus S, D'Amato T, Petit M, Thibaut F, Frébourg T, Campion D (May 2005). "Hyperprolinemia is a risk factor for schizoaffective disorder". Molecular Psychiatry 10 (5): 479–85. doi:10.1038/sj.mp.4001597. PMID 15494707.
- Bender HU, Almashanu S, Steel G, Hu CA, Lin WW, Willis A, Pulver A, Valle D (Mar 2005). "Functional consequences of PRODH missense mutations". American Journal of Human Genetics 76 (3): 409–20. doi:10.1086/428142. PMC 1196393. PMID 15662599.
- Rivera A, Maxwell SA (Aug 2005). "The p53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway". The Journal of Biological Chemistry 280 (32): 29346–54. doi:10.1074/jbc.M504852200. PMID 15914462.
- Pandhare J, Cooper SK, Phang JM (Jan 2006). "Proline oxidase, a proapoptotic gene, is induced by troglitazone: evidence for both peroxisome proliferator-activated receptor gamma-dependent and -independent mechanisms". The Journal of Biological Chemistry 281 (4): 2044–52. doi:10.1074/jbc.M507867200. PMID 16303758.
- Liu Y, Borchert GL, Surazynski A, Hu CA, Phang JM (Sep 2006). "Proline oxidase activates both intrinsic and extrinsic pathways for apoptosis: the role of ROS/superoxides, NFAT and MEK/ERK signaling". Oncogene 25 (41): 5640–7. doi:10.1038/sj.onc.1209564. PMID 16619034.
- Li D, He L (Oct 2006). "Association study of the G-protein signaling 4 (RGS4) and proline dehydrogenase (PRODH) genes with schizophrenia: a meta-analysis". European Journal of Human Genetics 14 (10): 1130–5. doi:10.1038/sj.ejhg.5201680. PMID 16791139.
External links
- Proline oxidase at the US National Library of Medicine Medical Subject Headings (MeSH)
|
|